PCVX Stock: Price, Earnings History and SEC Filings
Vaxcyte, Inc. (PCVX) last traded at $62.03, down 0.93% on the latest session and up 9.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.97 against an analyst estimate of $-1.47, a miss of 34.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PCVX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-1.97 | $-1.47 | -34.01% |
| Mar 2026 | May 6, 2026 | $-2.30 | $-1.86 | -23.66% |
| Dec 2025 | Feb 24, 2026 | $-1.80 | $-1.46 | -23.29% |
| Sep 2025 | Nov 4, 2025 | $-1.56 | $-1.27 | -22.83% |
PCVX beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
How PCVX reacts to earnings
Across its last 8 earnings releases, PCVX moved 5.3% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | +5.31% |
| 2026-05-06 | After close | -9.84% |
| 2026-02-24 | After close | +2.75% |
| 2025-11-04 | After close | -2.49% |
| 2025-08-06 | After close | -9.06% |
| 2025-05-07 | After close | +8.45% |
| 2025-02-25 | After close | -0.88% |
| 2024-11-05 | After close | -3.24% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
PCVX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$767M | -$669M | – | $-5.63 |
| 2024 | – | -$464M | -$475M | – | $-3.80 |
| 2023 | – | -$402M | -$313M | – | $-4.14 |
| 2022 | – | -$223M | -$176M | – | $-3.44 |
| 2021 | – | -$100M | -$128M | – | $-1.93 |
| 2020 | – | -$89M | -$48M | – | $-3.02 |
| 2019 | – | -$50M | -$48M | – | – |
| 2018 | – | -$29M | -$32M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PCVX
- 8-K · Oct 9, 2026Material agreement, New financial obligation, Other events
- 424B5 · Oct 8, 2026
- 424B5 · Oct 8, 2026
- 424B5 · Oct 6, 2026
- 424B5 · Oct 6, 2026
- 8-K · Oct 5, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Sep 3, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 15, 2026Officer or director change
Insider filing activity
PCVX insiders filed 17 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PCVX news
- Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?Oct 30, 2026 · finance.yahoo.com
- Vaxcyte Inc.Oct 27, 2026 · marketwatch.com
- Vaxcyte: Vaccine Titan In The MakingOct 19, 2026 · seekingalpha.com
About Vaxcyte, Inc.
Vaxcyte, Inc. (PCVX) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.